Is ZNTL or ACRV more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media prefer ZNTL or ACRV?

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Zentalis Pharmaceuticals' score of 0.62 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ACRV or AKBA?

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.94 beat Acrivon Therapeutics' score of 0.63 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akebia Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EDIT or ACRV?

In the previous week, Editas Medicine had 32 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 3 mentions for Acrivon Therapeutics. Editas Medicine's average media sentiment score of 0.77 beat Acrivon Therapeutics' score of 0.63 indicating that Editas Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Editas Medicine 7 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MGNX or ACRV?

In the previous week, MacroGenics and MacroGenics both had 3 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.63 beat MacroGenics' score of 0.31 indicating that Acrivon Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acrivon Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ACRV or NVCT?

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is ACRV or NVCT more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Acrivon Therapeutics N/A -64.43% -57.08% Nuvectis Pharma N/A -161.00% -98.88%

Acrivon Therapeutics (ACRV) Competitors

$1.56 -0.04 (-2.50%)

Closing price 04:00 PM Eastern

Extended Trading

$1.55 -0.01 (-0.58%)

As of 06:27 PM Eastern

Compare

ACRV vs. ZNTL, AKBA, EDIT, MGNX, and NVCT

Should you buy Acrivon Therapeutics stock or one of its competitors? MarketBeat compares Acrivon Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Acrivon Therapeutics include Zentalis Pharmaceuticals (ZNTL), Akebia Therapeutics (AKBA), Editas Medicine (EDIT), MacroGenics (MGNX), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical products" industry.

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 3 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 0.63 beat Zentalis Pharmaceuticals' score of 0.62 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals' return on equity of -53.61% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Acrivon Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.20	-$137.06M	-$1.73	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, indicating a potential upside of 46.57%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 647.86%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Zentalis Pharmaceuticals has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. 1.9% of Zentalis Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Acrivon Therapeutics beats Zentalis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.94 beat Acrivon Therapeutics' score of 0.63 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Akebia Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Akebia Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Akebia Therapeutics	$232.40M	1.18	-$5.34M	-$0.08	N/A

Acrivon Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Acrivon Therapeutics currently has a consensus price target of $11.67, suggesting a potential upside of 647.86%. Akebia Therapeutics has a consensus price target of $4.67, suggesting a potential upside of 357.52%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Acrivon Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Acrivon Therapeutics beats Akebia Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Editas Medicine presently has a consensus price target of $5.40, indicating a potential upside of 61.68%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 647.86%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Editas Medicine has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market.

In the previous week, Editas Medicine had 32 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 35 mentions for Editas Medicine and 3 mentions for Acrivon Therapeutics. Editas Medicine's average media sentiment score of 0.77 beat Acrivon Therapeutics' score of 0.63 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	7 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acrivon Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Acrivon Therapeutics' return on equity of -64.43% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Acrivon Therapeutics has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	8.07	-$160.06M	-$1.23	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Summary

Acrivon Therapeutics beats Editas Medicine on 8 of the 15 factors compared between the two stocks.

How does Acrivon Therapeutics compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are owned by institutional investors. 13.6% of MacroGenics shares are owned by insiders. Comparatively, 8.5% of Acrivon Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MacroGenics presently has a consensus price target of $5.50, indicating a potential upside of 32.85%. Acrivon Therapeutics has a consensus price target of $11.67, indicating a potential upside of 647.86%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

MacroGenics has higher revenue and earnings than Acrivon Therapeutics. MacroGenics is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.76	-$74.62M	-$1.10	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

In the previous week, MacroGenics and MacroGenics both had 3 articles in the media. Acrivon Therapeutics' average media sentiment score of 0.63 beat MacroGenics' score of 0.31 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MacroGenics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acrivon Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acrivon Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. Acrivon Therapeutics' return on equity of -64.43% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

MacroGenics has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Summary

Acrivon Therapeutics beats MacroGenics on 8 of the 14 factors compared between the two stocks.

How does Acrivon Therapeutics compare to Nuvectis Pharma?

Acrivon Therapeutics (NASDAQ:ACRV) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Acrivon Therapeutics presently has a consensus price target of $11.67, suggesting a potential upside of 647.86%. Nuvectis Pharma has a consensus price target of $10.00, suggesting a potential upside of 2.56%. Given Acrivon Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Acrivon Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Acrivon Therapeutics had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Acrivon Therapeutics and 1 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.43 beat Acrivon Therapeutics' score of 0.63 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Acrivon Therapeutics	Positive
Nuvectis Pharma	Positive

Acrivon Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 8.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Acrivon Therapeutics' return on equity of -64.43% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acrivon Therapeutics	N/A	-64.43%	-57.08%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Nuvectis Pharma is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Summary

Acrivon Therapeutics beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks.

Get Acrivon Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACRV vs. The Competition

Export

Metric	Acrivon Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$66.77M	$2.96B	$6.31B	$12.61B
Dividend Yield	N/A	1.83%	2.68%	5.22%
P/E Ratio	-0.78	18.17	21.13	26.68
Price / Sales	N/A	339.00	546.66	114.79
Price / Cash	N/A	55.97	27.44	37.60
Price / Book	0.44	4.02	9.95	6.88
Net Income	-$77.90M	$75.85M	$3.56B	$336.73M
7 Day Performance	-10.86%	2.06%	2.19%	4.20%
1 Month Performance	N/A	N/A	N/A	-0.08%
1 Year Performance	41.82%	30.32%	36.31%	40.26%

Acrivon Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACRV Acrivon Therapeutics	2.0652 of 5 stars	$1.56 -2.5%	$11.67 +647.9%	+45.5%	$66.77M	N/A	N/A	58
ZNTL Zentalis Pharmaceuticals	2.8457 of 5 stars	$4.01 -1.2%	$5.83 +45.5%	+229.2%	$285.47M	$67.43M	N/A	160	News Coverage Analyst Upgrade
AKBA Akebia Therapeutics	3.2725 of 5 stars	$1.05 +2.5%	$4.67 +346.6%	-66.3%	$280.33M	$232.40M	N/A	430
EDIT Editas Medicine	3.3921 of 5 stars	$2.84 +2.9%	$5.40 +90.1%	+99.4%	$278.06M	$40.52M	N/A	230	Gap Down High Trading Volume
MGNX MacroGenics	2.4987 of 5 stars	$4.35 -4.0%	$5.50 +26.4%	+203.4%	$276.49M	$149.50M	N/A	430	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACRV) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ZNTL, AKBA, EDIT, MGNX, and NVCT

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Summary

How does Acrivon Therapeutics compare to Editas Medicine?

Summary

How does Acrivon Therapeutics compare to MacroGenics?

Summary

How does Acrivon Therapeutics compare to Nuvectis Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acrivon Therapeutics (ACRV) Competitors

ACRV vs. ZNTL, AKBA, EDIT, MGNX, and NVCT

How does Acrivon Therapeutics compare to Zentalis Pharmaceuticals?

Does the media prefer ZNTL or ACRV?

Is ZNTL or ACRV more profitable?

Which has preferable valuation and earnings, ZNTL or ACRV?

Do analysts recommend ZNTL or ACRV?

Which has more volatility and risk, ZNTL or ACRV?

Do institutionals and insiders believe in ZNTL or ACRV?

Summary

How does Acrivon Therapeutics compare to Akebia Therapeutics?

Do institutionals & insiders hold more shares of ACRV or AKBA?

Does the media favor ACRV or AKBA?

Is ACRV or AKBA more profitable?

Which has higher valuation & earnings, ACRV or AKBA?

Which has more volatility and risk, ACRV or AKBA?

Do analysts rate ACRV or AKBA?

Summary

How does Acrivon Therapeutics compare to Editas Medicine?

Do analysts recommend EDIT or ACRV?

Which has more risk and volatility, EDIT or ACRV?

Does the media favor EDIT or ACRV?

Do insiders & institutionals believe in EDIT or ACRV?

Is EDIT or ACRV more profitable?

Which has higher valuation & earnings, EDIT or ACRV?

Summary

How does Acrivon Therapeutics compare to MacroGenics?

Do institutionals & insiders have more ownership in MGNX or ACRV?

Do analysts prefer MGNX or ACRV?

Which has higher earnings & valuation, MGNX or ACRV?

Does the media prefer MGNX or ACRV?

Is MGNX or ACRV more profitable?

Which has more risk & volatility, MGNX or ACRV?

Summary

How does Acrivon Therapeutics compare to Nuvectis Pharma?

Do analysts rate ACRV or NVCT?

Does the media refer more to ACRV or NVCT?

Which has more volatility & risk, ACRV or NVCT?

Do insiders and institutionals hold more shares of ACRV or NVCT?

Is ACRV or NVCT more profitable?

Which has higher earnings and valuation, ACRV or NVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACRV vs. The Competition

Acrivon Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools